Neurochemical studies with St. John's wort in vitro
- PMID: 11518063
- DOI: 10.1055/s-2001-15475
Neurochemical studies with St. John's wort in vitro
Abstract
The effect of extracts and constituents of St. John's wort, Hypericum perforatum, at various CNS receptors were studied by radioligand binding techniques in order to determine a profile of pharmacological activity in vitro. Binding inhibition was examined for the G-protein coupled opioid, serotonin (5-HT), histamine, neurokinin and corticotropin releasing factor (CRF) receptors, for the steroid estrogen-alpha receptor and for the ligand-gated ionchannel GABA(A) receptor. Hypericin showed the most potent binding inhibiton of all tested constituents to human CRF1 receptor with an IC50 value of 300 nM. Preliminary GTPgamma35S binding studies to CRF1 coupled G-protein indicated an antagonistic action for hypericin. The acylphloroglucinole hyperforin failed to inhibit 125I-astressin binding to hCRF, receptor up to 10 microM. Hyperforin inhibited binding to opioid and serotonin (5-HT) receptors at IC50 values between 0.4 and 3 microM, while hypericin and pseudohypericin inhibited with weaker potency. The biflavonoid I3,II8-biapigenin inhibited 3H-estradiol binding to the estrogen-alpha receptor with an IC50 value of 1 microM. The inhibition of 3H-muscimol binding to the GABA(A) receptor is likely to be exclusively due to GABA present in the extract. We therefore hypothesize that additive or synergistic actions of several ditsinct compounds may be responsible for the beneficial antidepressant effect of St. John's wort.
Similar articles
-
In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.Pharmacopsychiatry. 2001 Jul;34 Suppl 1:S45-8. doi: 10.1055/s-2001-15458. Pharmacopsychiatry. 2001. PMID: 11518075
-
Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):59-74. doi: 10.3109/10799899909036637. J Recept Signal Transduct Res. 1999. PMID: 10071750
-
Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John's wort.Planta Med. 2005 Jul;71(7):592-8. doi: 10.1055/s-2005-871262. Planta Med. 2005. PMID: 16041642
-
Mechanism of action of St John's wort in depression : what is known?CNS Drugs. 2003;17(8):539-62. doi: 10.2165/00023210-200317080-00001. CNS Drugs. 2003. PMID: 12775192 Review.
-
Current St John's wort research from mode of action to clinical efficacy.Pharmacol Res. 2003 Feb;47(2):101-9. doi: 10.1016/s1043-6618(02)00266-9. Pharmacol Res. 2003. PMID: 12543057 Review.
Cited by
-
Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds.Front Fungal Biol. 2023 Nov 29;4:1295223. doi: 10.3389/ffunb.2023.1295223. eCollection 2023. Front Fungal Biol. 2023. PMID: 38094868 Free PMC article.
-
Therapeutics to Treat Psychiatric and Neurological Disorders: A Promising Perspective from Algerian Traditional Medicine.Plants (Basel). 2023 Nov 15;12(22):3860. doi: 10.3390/plants12223860. Plants (Basel). 2023. PMID: 38005756 Free PMC article. Review.
-
Clinical relevance of St. John's wort drug interactions revisited.Br J Pharmacol. 2020 Mar;177(6):1212-1226. doi: 10.1111/bph.14936. Epub 2020 Jan 17. Br J Pharmacol. 2020. PMID: 31742659 Free PMC article. Review.
-
Synergistic Effects of Plant Derivatives and Conventional Chemotherapeutic Agents: An Update on the Cancer Perspective.Medicina (Kaunas). 2019 Apr 17;55(4):110. doi: 10.3390/medicina55040110. Medicina (Kaunas). 2019. PMID: 30999703 Free PMC article. Review.
-
Interaction of Plant Extracts with Central Nervous System Receptors.Medicines (Basel). 2017 Feb 23;4(1):12. doi: 10.3390/medicines4010012. Medicines (Basel). 2017. PMID: 28930228 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
